IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Cell therapy isn't a new field, but only recent tech and medical advances have made these therapies commercially available for patients. As more cell therapies have received FDA approval over the past two decades, developers have been at the forefront of life sciences innovation, attracting significant interest and investment. However, the current regulatory environment hasn't kept pace with the rapidly evolving cell therapy landscape. A lack of clarity in regulatory guidelines continues to create confusion and uncertainty for manufacturers and developers, while lengthy approval processes delay patient access to treatments and companies’ opportunities to earn profit. Still, strong investor interest and an active funding environment point to the promise of cell therapies, as seen in robust revenue growth—accelerating at a CAGR of 1.2% to an estimated $3.2 billion over the past five years.
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the Cell Therapy industry in the United States includes market sizing, forecasting, data and analysis from 2015-2030. The most recent publication was released September 2025.
The Cell Therapy industry in the United States operates under the NAICS industry code OD4040. Cell therapy companies research, develop, manufacture and commercialize cell-based therapies. They specialize in discovering the therapeutic potential of living cells to treat diseases and medical conditions. Cell therapy companies focus on developing innovative treatments that use various types of cells, including stem cells, immune cells or genetically modified cells, to address multiple health issues. Related terms covered in the Cell Therapy industry in the United States include blockbuster drug, intellectual property, venture capital and stem cell.
Products and services covered in Cell Therapy industry in the United States include Infectious disease cell therapies, Central nervous system cell therapies and Oncology cell therapies.
Companies covered in the Cell Therapy industry in the United States include Novartis International Ag.
The Performance chapter covers detailed analysis, datasets, detailed current performance, sources of volatility and an outlook with forecasts for the Cell Therapy industry in the United States.
Questions answered in this chapter include what's driving current industry performance, what influences industry volatility, how do successful businesses overcome volatility, what's driving the industry outlook. This analysis is supported with data and statistics on industry revenues, costs, profits, businesses and employees.
The Products and Markets chapter covers detailed products and service segmentation and analysis of major markets for the for the Cell Therapy industry in the United States.
Questions answered in this chapter include how are the industry's products and services performing, what are innovations in industry products and services, what products or services do successful businesses offer and what's influencing demand from the industry's markets. This includes data and statistics on industry revenues by product and service segmentation and major markets.
The Geographic Breakdown chapter covers detailed analysis and datasets on regional performance of the Cell Therapy industry in the United States.
Questions answered in this chapter include where are industry businesses located and how do businesses use location to their advantage. This includes data and statistics on industry revenues by location.
The Competitive Forces chapter covers the concentration, barriers to entry and supplier and buyer profiles in the Cell Therapy industry in the United States. This includes data and statistics on industry market share concentration, barriers to entry, substitute products and buyer & supplier power.
Questions answered in this chapter include what impacts the industry's market share concentration, how do successful businesses handle concentration, what challenges do potential industry entrants face, how can potential entrants overcome barriers to entry, what are substitutes for industry services, how do successful businesses compete with substitutes and what power do buyers and suppliers have over the industry and how do successful businesses manage buyer & supplier power.
The Companies chapter covers Key Takeaways, Market Share and Companies in the Cell Therapy industry in the United States. This includes data and analysis on companies operating in the industry that hold a market share greater than 5%.
Questions answered in this chapter include what companies have a meaningful market share and how each company is performing.
The External Environment chapter covers Key Takeaways, External Drivers, Regulation & Policy and Assistance in the Cell Therapy industry in the United States. This includes data and statistics on factors impacting industry revenue such as economic indicators, regulation, policy and assistance programs.
Questions answered in this chapter include what demographic and macroeconomic factors impact the industry, what regulations impact the industry, what assistance is available to this industry.
The Financial Benchmarks chapter covers Key Takeaways, Cost Structure, Financial Ratios, Valuation Multiples and Key Ratios in the Cell Therapy industry in the United States. This includes financial data and statistics on industry performance including key cost inputs, profitability, key financial ratios and enterprise value multiples.
Questions answered in this chapter include what trends impact industry costs and how financial ratios have changed overtime.
The Industry Data chapter includes 10 years of historical data with 5 years of forecast data covering statistics like revenue, industry value add, establishments, enterprises, employment and wages in the Cell Therapy industry in the United States.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
The market size of the Cell Therapy industry in the United States is $3.2bn in 2026.
There are 742 businesses in the Cell Therapy industry in the United States, which has grown at a CAGR of 5.8 % between 2020 and 2025.
The Cell Therapy industry in the United States is unlikely to be materially impacted by import tariffs with imports accounting for a low share of industry revenue.
The Cell Therapy industry in the United States is unlikely to be materially impacted by export tariffs with exports accounting for a low share of industry revenue.
The market size of the Cell Therapy industry in the United States has been growing at a CAGR of 1.2 % between 2020 and 2025.
Over the next five years, the Cell Therapy industry in the United States is expected to grow.
The biggest company operating in the Cell Therapy industry in the United States is Novartis International Ag
Development and production of skin and chronic wound cell therapy products and Development and production of musculoskeletal cell therapy products are part of the Cell Therapy industry in the United States.
The company holding the most market share in the Cell Therapy industry in the United States is Novartis International Ag.
The level of competition is moderate and increasing in the Cell Therapy industry in the United States.